Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, even if its incidence has decreased over time, mainly because of prevention and treatment of Helicobacter pylori infection. Contrarily, the incidence of gastro-esophageal junction (GEJ) adenocarcinomas has increased, attributable to smoking and elevated body mass index (BMI) . Much progress has been made in the management of advanced G/GEJ adenocarcinomas: the identification of molecular sub-groups benefiting from specific therapies (HER2 positive tumors, MSI/dMMR and EBV positive tumors, FGFR amplified tumors, etc)[3 –6], the introduction of immune checkpoint inhibitors both in monotherapy in pretreated patients and in combination with chemotherapy in the first-line setting, and the early introduction of nutritional support, physical activity and other supportive care.